QUIT MEXC RealStocks
Own real QUIT shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-13 23:50:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Achieve Life Sciences, Inc. (QUIT) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $6.32, with a market capitalization of $692.12M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.91 to $6.78. This page covers its latest market performance, valuation, price trends and company information.
$692.12M | |
$6.30 | |
$6.52 | |
$5.91 | |
$6.29 | |
702.53K | |
652.03K | |
-- | |
$6.78 | |
$5.91 | |
-- | |
-- |
Achieve Life Sciences, Inc. (QUIT) is trading at $6.18 in after-hours trading as of 2026-11-13 22:02:00, down 2.36% ($0.15) from the regular-session close of $6.32.
After-hours trading shows how investors are pricing QUIT after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Achieve Life Sciences, Inc. (QUIT) moved from $6.40 to $6.32, representing a decline of 1.19% ($0.08).
The stock traded between $5.91 and $6.78 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 652.03 thousand shares, -- versus the previous seven-day period, indicating -- trading activity.
Position in Range: 47.8%
QUIT is currently trading at $6.32, placing it 47.8% of the way from its 52-week low of $5.91 to its 52-week high of $6.78. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Achieve Life Sciences Inc is a late-stage specialty pharmaceutical company focused on the world-wide development and commercialization of cytisinicline as a treatment for nicotine dependence. Its New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two completed Phase 3 studies and an open-label long-term safety study. It has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.
| Employees | 28 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Achieve Life Sciences, Inc. (QUIT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to QUIT, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between QUIT shares and USD.
QUIT Shares to USD
1.00 QUIT shares = 6.324 USD
Calculations are estimates based on the latest available price and are for reference only.